Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report

BACKGROUND: PD-1 checkpoint inhibitors have shown a robust tumor response in the treatment of various cancers. Pembrolizumab is an anti-PD-1 checkpoint antibody approved for the treatment of unresectable or metastatic melanoma in more than 40 countries. Although autoimmune pneumonitis is considered...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Wan, Zhang, Xiangmei, Li, Wenwen, Kong, Cheng, Wang, Yuanyang, Zhu, Lianyu, Xu, Ruilian, Deng, Guofang, Zhang, Peize
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204878/
https://www.ncbi.nlm.nih.gov/pubmed/30425530
http://dx.doi.org/10.2147/OTT.S178246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204878/
https://www.ncbi.nlm.nih.gov/pubmed/30425530
http://dx.doi.org/10.2147/OTT.S178246

Ejemplares similares